Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway

NDA FilingIlluccixGozellixPositive

AI Analysis

Summary

Telix Pharmaceuticals completed enrollment in its Phase 3 BiPASS study of PSMA-PET imaging agents Illuccix and Gozellix for prostate cancer imaging and aligned with the FDA on an NDA pathway that could support reimbursement and patient access if approved.

Clinical Trial Data

Phase

Phase 3

Outcome Details

Telix has aligned with FDA on NDA pathway for BiPASS study; approval would support reimbursement and broaden patient access

Importance:7/10

Sentiment:

0.70

Phase 3enrollment completeNDA pathwayoncologyimagingprostate cancerPSMA-PET

Related Companies

$TLX

Read the original article

Published by GlobeNewswire Clinical Studies on September 1, 2026 10:18 PM

Read Original